SSSven‐Erik Sonesson

Sven‐Erik Sonesson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sven‐Erik Sonesson has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Quantification of Anti‐Ro52, Anti‐Ro60 and Anti‐La Autoantibodies at High Sample Dilution and Their Predictive Value for Congenital Heart Block

    by Lisa Rudolph, Elina Richardsdotter Möller, Rui Da Silva Rodrigues, Gregoire Martin de Fremont, Vijole Ottosson, Linda Lagnefeld, Iva Gunnarsson, Elisabet Svenungsson, Felicia Nordenstam, Gunnar Bergman, et al.

    Maternal anti‐Ro/La antibodies confer a risk of congenital heart block (CHB), but current methods for predicting risk relying on the presence or absence of these autoantibodies perform poorly. To identify more accurate biomarkers of CHB risk, we investigated the association between maternal levels of autoantibodies and the risk of CHB. A total of 318 women positive for anti‐Ro/SSA autoantibodies were included. Autoantibody presence was obtained from health records for all, and ELISA was used to quantify levels of anti‐Ro52, anti‐Ro60, and anti‐La in a subset of 116 women with samples obtained during pregnancy, including 27 CHB‐affected pregnancies. Predictive models for CHB risk were developed using logistic regression and machine learning. Anti‐Ro/SSA positive women with anti‐Ro60 were more likely to have pregnancies with CHB ( p < 0.05). Levels of both anti‐Ro60 ( p < 0.001) and anti‐Ro52 ( p < 0.05) were significantly higher in CHB‐affected pregnancies and correlated ( r = 0.8, p < 0.0001), while levels of anti‐La did not differ between groups. Levels of anti‐Ro60 were identified as the strongest individual predictor of CHB, with a relative risk of 16.3 (95% CI 1.04–255.0, p < 0.001) for the top versus the bottom decile. In all tested combinations, models that included anti‐Ro60 levels outperformed models that did not. Models based on anti‐Ro60 levels alone reached an area under the curve (AUC) of 0.76 and an odds ratio (OR) per standard deviation increase of 2.8 (95% CI 1.6–5.3). These findings confirm a strong association between maternal anti‐Ro antibody levels and CHB risk in anti‐SSA‐positive pregnancy, highlighting anti‐Ro60 autoantibody levels as a valuable biomarker in risk stratification.

  • Open Access

    Atrioventricular conduction abnormalities are associated with poor outcome following intermittent umbilical cord occlusions in fetal sheep

    by Juulia Lantto, Jonas Johnson, Heikki Huhta, Mervi Haapsamo, Panu Kiviranta, Kati Räsänen, Hanna‐Marja Voipio, Sven‐Erik Sonesson, Juha Voipio, Juha Räsänen, et al.

    Introduction: Fetal arrhythmias have been described with intrapartum hypoxemia; however, they cannot be accurately diagnosed with currently used fetal heart rate (FHR) monitoring systems due to low resolution and signal averaging. We used a Holter device to record electrocardiogram (ECG) at 250 Hz in term sheep fetuses that developed severe metabolic acidosis induced by intermittent umbilical cord occlusions (UCOs), mimicking human labor contractions. We hypothesized that UCOs leading to worsening fetal metabolic acidosis provoke distinct fetal arrhythmias that could indicate impending fetal death.Material and Methods: Thirteen pregnant sheep (gestational age 133–135/145 days) were instrumented under general anesthesia. Three electrodes were placed on the fetal chest and connected to a Holter device for continuous ECG recording at a sampling rate of 250 Hz. The fetal axillary artery was catheterized and an inflatable occluder was placed around the umbilical cord. After a 4–5 day recovery, complete UCOs were induced by inflating the occluder for 1 min, followed by deflation for 2 min, until the fetal arterial pH dropped <7.0 and/or base excess (BE) <−16. Thereafter, an emergency cesarean section was performed to deliver the fetus.Results: Eight sheep fetuses were included in the final analysis. All fetuses had normal baseline arterial blood gases and lactate values. During the first two UCOs, all fetuses demonstrated isolated benign arrhythmias. Three fetuses that developed severe metabolic acidosis after five UCOs showed persistent atrioventricular (AV) conduction abnormalities during the last UCO and its release, requiring cardiopulmonary resuscitation (CPR) at birth. One fetus with third‐degree AV block had no detectable QRS complexes at birth, developed ventricular tachycardia and fibrillation (VT/VF) during CPR, and was successfully defibrillated. Five fetuses tolerated ≥10 UCOs before developing severe metabolic acidosis, and none of these showed any persistent AV‐conduction abnormalities, though one fetus died after developing VT/VF after the 10th UCO.Conclusions: Metabolic acidemia induced by intermittent UCOs in term sheep fetuses is associated with various arrhythmias, some of which may be life‐threatening. Continuous intrapartum fetal ECG recording at a sample rate of ≥250 Hz coupled with a software capable of automatically detecting significant arrhythmias could enhance intrapartum fetal monitoring in the future.


  • Open Access

    Impact of early detection and steroid treatment on fetal ventricular heart rate and pacemaker implantation in anti‐Ro/SSA positive congenital heart block

    by Sven‐Erik Sonesson, Aurelie Ambrosi, Felicia Nordenstam, Håkan Eliasson, Marie Wahren‐Herlenius

    Introduction: We investigated the effects of timing of detection and transplacental fluorinated steroid treatment on ventricular heart rate (HR) and age at pacemaker implantation in fetal third‐degree atrioventricular block (AVB).Material and Methods: Twenty‐five of 31 fetuses diagnosed with Ro/SSA autoantibody‐positive AVB II‐III at our tertiary fetal cardiology center (2000–2020) and AVB III as final feto‐neonatal outcome were reviewed.Results: AVB was detected approximately 5 weeks earlier in pregnancy if followed in a surveillance program compared to cases referred from primary care for bradycardia (20.6 [2.3] [mean (SD)] vs. 25.4 [3.2] weeks, p = 0.001). AVB detected before 24 weeks had higher HR than those detected later in gestation (63.3 [6.9] vs. 57.2 [6.9] bpm, p = 0.042), with a larger proportion having HR >60 bpm (80% vs. 33%, p = 0.041). The 17/25 cases that received treatment with fluorinated steroid were diagnosed earlier in gestation, with higher HR at diagnosis (61.7 [7.1] vs. 54.7 [6.3] bpm, p = 0.026), 1–2 weeks after diagnosis/treatment start, and before birth (65.4 [12.4] vs. 54.9 [5.7] bpm, p = 0.030) than untreated cases. Overall, 11 cases were commenced on betamimetics: three at diagnosis and eight at or after the examination made 1–2 weeks after diagnosis/treatment start, without any HR improvement. Two of 24 surviving babies were born preterm, and 4/24 received a neonatal pacemaker. Age at pacemaker implantation correlated significantly with HR before birth (Spearman R 0.57, p = 0.004), and fetuses with HR >60 bpm had a higher rate of pacemaker‐free survival at three (90% vs. 40%, p = 0.018) and 12 months of age (80% vs. 13%, p = 0.002). The same trend was observed in pacemaker‐free survival at 3 months of age in fluorinated steroid‐treated compared to untreated cases (71% vs. 38%, ns).Conclusions: Our data confirm that AVB III detected earlier in gestation have a higher HR, and suggest that this higher HR can be successfully maintained to the end of gestation in cases treated with fluorinated steroids. Fetuses with HR >60 bpm before birth had a lower rate of pacemaker implantation at 3 and 12 months of age.


  • Open Access

    Fetal cardiac function at intrauterine transfusion assessed by automated analysis of color tissue Doppler recordings

    by Lotta Herling, Jonas Johnson, Kjerstin Ferm-Widlund, Fredrik Bergholm, Peter Lindgren, Sven-Erik Sonesson, Ganesh Acharya, Magnus Westgren

    Background: Fetal anemia is associated with a hyperdynamic circulation and cardiac remodeling. Rapid intrauterine transfusion (IUT) of blood with high hematocrit and viscosity into the umbilical vein used to treat this condition can temporarily further affect fetal heart function. The aim of this study was to evaluate the short-term changes in fetal myocardial function caused by IUT using automated analysis of cine-loops of the fetal heart obtained by color tissue Doppler imaging (cTDI). Methods: Fetal echocardiography was performed before and after IUT. cTDI recordings were obtained in a four-chamber view and regions of interest were placed at the atrioventricular plane in the left ventricular (LV), right ventricular (RV) and septal walls. Myocardial velocities were analyzed by an automated analysis software to obtain peak myocardial velocities during atrial contraction (Am), ventricular ejection (Sm), rapid ventricular filling (Em) and Em/Am ratio was calculated. Myocardial velocities were converted to z-scores using published reference ranges. Delta z-scores (after minus before IUT) were calculated. Correlations were assessed between variables and hemoglobin before IUT. Results: Thirty-two fetuses underwent 70 IUTs. Fourteen were first time transfusions. In the LV and septal walls, all myocardial velocities were significantly increased compared to normal values, whereas in the RV only Sm was increased before IUT (z-scores 0.26–0.52). In first time IUTs, there was a negative correlation between LV Em (rho = − 0.61, p = 0.036) and LV Em/Am (rho = − 0.82, p = 0.001) z-scores and hemoglobin before IUT. The peak myocardial velocities that were increased before IUT decreased, whereas LV Em/Am increased significantly after IUT. Conclusions: This study showed that peak myocardial velocities assessed by cTDI are increased in fetuses before IUT reflecting the physiology of hyperdynamic circulation. In these fetuses, the fetal heart is able to adapt and efficiently handle the volume load caused by IUT by altering its myocardial function.


  • Benefits of fetal echocardiographic surveillance in pregnancies at risk of congenital heart block: single‐center study of 212 anti‐Ro52‐positive pregnancies

    by S.‐E. Sonesson, A. Ambrosi, M. Wahren‐Herlenius

    Objectives: Assuming that autoimmune congenital heart block (CHB) is a progressive disease amenable to therapeutic modulation, we introduced a surveillance program for at‐risk pregnancies with the dual aim of investigating if fetal atrioventricular block (AVB) could be detected and treated before becoming complete and irreversible, and to establish the incidence of AVB I, II and III in a large prospective cohort.Methods: This was a prospective study of 212 anti‐Ro52 antibody‐exposed pregnancies at risk of fetal AVB that were followed weekly between 18 and 24 weeks' gestation at our tertiary fetal cardiology center from 2000 to 2015. A 12‐lead electrocardiogram (ECG) was recorded within 1 week after birth. Fetal Doppler atrioventricular (AV) intervals were converted to Z‐scores using reference standard values derived from normal pregnancies. Each fetus was represented by the average value of the two recordings, obtained at two consecutive visits, which resulted in the longest AV interval. AV interval values were classified into normal AV conduction (Z‐score ≤ 2.0) and three levels of delayed AV conduction: Z‐score > 2.0 and ≤ 3.0, Z‐score > 3.0 and ≤ 4.0, and Z‐score > 4.0.Results: AVB II or III developed in 6/204 (2.9%) pregnancies without a CHB history and 1/8 (12.5%) of those with a CHB history. AV intervals > 2 and ≤ 3, > 3 and ≤ 4, and > 4 were detected in 16.0%, 7.5% and 2.8% of cases, respectively, and were related to the PR interval on 185 available ECGs. Three of the five cases with AVB III and one of two cases with 2:1 AVB II developed within 1 week of AV interval Z‐score of 1.0, 1.9, 2.8 and 1.9, respectively. Transplacental treatment with betamethasone was associated with restoration of 1:1 AV conduction in the two fetuses with AVB II, with a better long‐term result (normal ECG vs AVB I or II) observed in the case in which treatment was started within 1 week after AVB developed. Betamethasone treatment did not reverse AVB III, although a temporary effect on AV conduction was observed in 1/5 cases. Notably, the three cases in which treatment was started within 1 week after AVB III development responded with a higher ventricular rate than the other two cases and did not require pacemaker implantation until a later age (2–5 years vs 1.5–2 months).Conclusion: Fetal AV interval is a poor predictor of CHB progression, but CHB surveillance still allows detection of fetuses with AVB II or III shortly after its development, allowing for timely treatment initiation and potentially better outcome. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.


  • Factors influencing fetal cardiac conduction in anti-Ro/SSA-positive pregnancies

    by Sven-Erik Sonesson, Malin Hedlund, Aurélie Ambrosi, Marie Wahren-Herlenius

    Congenital heart block (CHB) develops in 1–2% of anti-Ro/SSA-positive pregnancies and has a recurrence rate of 12–20%, which indicates that factors other than maternal autoantibodies are crucial for CHB to occur. Here, we aimed to evaluate the influence of factors previously associated with CHB on the occurrence of milder forms of fetal cardiac conduction disturbances, shown to occur in up to 30% of anti-Ro/SSA-positive pregnancies, and on neonatal outcome in a large cohort of prospectively followed pregnancies. The association of maternal age, season of the year and history of atrioventricular block (AVB) with the development of fetal Doppler and neonatal ECG conduction disturbances was evaluated in 212 anti-Ro52/SSA-positive singleton pregnancies. Maternal age was significantly higher in AVB II–III pregnancies but was not correlated with fetal AV time intervals in fetuses without signs of AVB II–III. AV time intervals of fetuses surveilled during the winter were significantly longer than those of fetuses surveilled during the summer. Fetal AV time intervals in consecutive pregnancies from the same women were significantly correlated. A history of AVB II–III was associated with significantly longer AV time intervals, and AVB I–III was observed at birth in 38% of babies born after a sibling with abnormal fetal AV conduction. Our study shows that AV time intervals in anti-Ro/SSA antibody-exposed fetuses during the CHB risk period are influenced by the season of the year, and reveals that the recurrence of conduction disturbances in antibody-exposed fetuses is higher than previously reported when milder forms are taken into account.


  • Hemodynamic aspects of normal human feto‐placental (umbilical) circulation

    by Ganesh Acharya, Sven‐Erik Sonesson, Kari Flo, Juha Räsänen, Anthony Odibo

    Understanding the changes in normal circulatory dynamics that occur during the course of pregnancy is essential for improving our knowledge of pathophysiological mechanisms associated with feto-placental diseases. The umbilical circulation is the lifeline of the fetus, and it is accessible for noninvasive assessment. However, not all hemodynamic parameters can be reliably measured in utero using currently available technology. Experimental animal studies have been crucial in validating major concepts related to feto-placental circulatory physiology, but caution is required in directly translating the findings of such studies into humans due to species differences. Furthermore, it is important to establish normal reference ranges and take into account gestational age associated changes while interpreting the results of clinical investigation. Therefore, it is necessary to critically evaluate, synthesize and summarize the knowledge available from the studies performed on human pregnancies to be able to appropriately apply them in clinical practice. This narrative review is an attempt to present contemporary concepts on hemodynamics of feto-placental circulation based on human studies.


  • Hemodynamics in fetal arrhythmia

    by Sven‐Erik Sonesson, Ganesh Acharya

    Fetal arrhythmias are among the few conditions that can be managed in utero. However, accurate diagnosis is essential for appropriate management. Ultrasound‐based imaging methods can be used to study fetal heart structure and function noninvasively and help to understand fetal cardiovascular pathophysiology, and they remain the mainstay of evaluating fetuses with arrhythmias in clinical settings. Hemodynamic evaluation using Doppler echocardiography allows the elucidation of the electrophysiological mechanism and helps to make an accurate diagnosis. It can also be used as a tool to understand fetal cardiac pathophysiology, for assessing fetal condition and monitoring the effect of antiarrhythmic treatment. This narrative review describes Doppler techniques that are useful for evaluating fetal cardiac rhythms to refine diagnosis and provides an overview of hemodynamic changes observed in different types of fetal arrhythmia.


  • Outcome in 212 anti‐Ro/SSA‐positive pregnancies and population‐based incidence of congenital heart block

    by Amanda Skog, Linda Lagnefeldt, Peter Conner, Marie Wahren‐Herlenius, Sven‐Erik Sonesson

    Introduction: We investigated the effects of maternal autoimmune disease and fetal congenital heart block (CHB) on pregnancy outcomes in anti‐Ro/SSA‐positive women and assessed the population‐based incidence of isolated CHB.Material and methods: One hundred and ninety nine anti‐Ro/SSA‐positive pregnancies were prospectively followed at our center (2000–2013). Seven fetuses developed atrioventricular block (AVB) II–III. In this period, another 13 anti‐Ro/SSA‐positive pregnancies were referred for fetal bradycardia, subsequently diagnosed with AVB II–III. Cesarean section rates, gestational age, body measurements at birth, and the incidence of CHB in these 212 pregnancies were analyzed in relation to fetal atrioventricular conduction and maternal diagnosis and compared with data from the Medical Birth Registry on 352 104 pregnancies in the Stockholm County.Results: The prevalence of maternal systemic lupus erythematosus (SLE) and primary Sjögren's syndrome and the outcomes at birth were similar in normal conduction and AVB I cases. Only 1/20 AVB II–III cases (0/7 in the surveillance group) had a mother diagnosed with SLE, compared with 73/192 in cases with normal conduction or AVB I. Excluding cases with AVB II–III, SLE mothers more frequently delivered by cesarean section (31% vs. 20%, p < 0.05) and had a higher incidence of preterm birth (13% vs. 5.8%, p < 0.05) than the county population. Both SLE and primary Sjögren's syndrome mothers had a fourfold greater rate of growth‐retarded babies (10.11% vs. 2.2%, p < 0.001). The incidence of autoantibody‐related AVB II–III in Stockholm County was 1/23 300.Conclusion: This study of CHB provides new information on the incidence of CHB and outcome of pregnancy in anti‐Ro/SSA‐positive women, which has clinical relevance when counseling rheumatic patients considering pregnancy.